Medindia
Advertisement

Is Immunotherapy the Right Choice for Colorectal Cancer Patients

by Colleen Fleiss on May 4, 2019 at 9:04 PM

Is Immunotherapy the Right Choice for Colorectal Cancer Patients
The degree of tumor mutation a patient with metastatic colorectal cancer is linked to varying responses to immunotherapy when considered in combination with an established biomarker called "microsatellite instability (MSI)", stated study published in the journal Annals of Oncology. Foundational research by a City of Hope physician-scientist and his colleagues could one day help metastatic colorectal cancer patients decide whether to choose immunotherapy or chemotherapy as their first treatment option.

"Immunotherapy is the new, hot thing, but sometimes traditional chemotherapy can be a better choice," said Marwan Fakih, M.D., senior author of the new study and co-director of the Gastrointestinal Cancer Program at City of Hope. "Our study suggests tumor genomics could help doctors decide what kind of treatment will benefit each patient most. Taking this kind of personalized medicine approach, we will be able to provide patients with options that yield better outcomes and are more cost-effective."
Advertisement


"Comprehensive genomic profiling is critical to assess the underlying genomic drivers of a tumor, as well as important biomarkers that require broad DNA interrogation like tumor mutational burden (TMB) and microsatellite instability (MSI)," said Alexa Schrock, Ph.D., associate director of clinical development at Foundation Medicine. "In this study, we've seen the importance of evaluating both TMB and MSI when making treatment decisions for metastatic colorectal cancer patients."

At the moment, doctors rely only on MSI status to determine which metastatic colorectal cancer patients receive immunotherapy, Fakih said. He's working to refine the markers that predict patient response to immunotherapy to improve the prognosis for colorectal cancer, the third most commonly diagnosed cancer in the world, according to the World Health Organization. Although this type of cancer has been on the decline, it is on the rise among young adults.
Advertisement

"Finding methods to identify the right, personalized treatment for a patient is top-of-mind, especially in today's precision medicine landscape," Fakih said. "This study is the first to use degree of tumor mutation as a predictor of response to immunotherapy in metastatic colorectal cancer patients with MSI. For cancer patients, timely, appropriate treatment is imperative." Fakih and his colleagues retrospectively analyzed the data of 22 patients - all of whom had high MSI, a biomarker that indicates they're a good candidate to receive immune checkpoint inhibitor treatment. The patients received either pembrolizumab or nivolumab, both of which are U.S. Food and Drug Administration-approved for metastatic colorectal cancer patients.

The scientists looked at tumor characteristics, tumor genomics and outcome data and compared those analyses to a database containing 18,140 metastatic colorectal cancer patients.

The patients whose tumor cells had a mutation score less than a cut-off point of 37 were less likely to respond to immunotherapy and more likely to have their disease quickly worsen. Those who had a tumor mutation score above the cut-off point of 41 were more likely to respond to pembrolizumab or nivolumab. Notably, the patients who responded to immunotherapy appeared to have durable responses, with the majority experiencing ongoing major shrinkage beyond 1.5 years (the time of study analysis).

The implication is that patients with MSI and a high tumor mutation score should consider receiving immunotherapy as their first treatment, Fakih said. Those with MSI and a low tumor mutation score (less than 37) should be considered for chemotherapy rather than immunotherapy as their first treatment option, Fakih added. Of course, more research is needed to validate these important findings.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
'Hybrid Immunity' may Help Elude COVID-19 Pandemic
Stroop Effect
Plant-Based Diet may Reduce the Risk of COVID-19
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Cancer and Homeopathy Immunisation Colo-rectal cancer - Management Colorectal Cancer Cancer Facts Cancer Tattoos A Body Art Dealing with Pollen Allergy Colon Polyps Colorectal Cancer Screening 

Recommended Reading
Colo-rectal cancer - Management
Treatment for Colorectal Cancers may involve surgery,chemotherapy, radiation therapy or biological ....
Quiz on Colon
Are you suffering from a migraine? It is possible that you have an unhealthy bowel. Strange - but .....
Colorectal Cancer Awareness Month – Time to Get Screened
The month of March every year is dedicated to Colorectal Cancer Awareness and the emphasis is on ......
Cancer Immunotherapy
Cancer immunotherapy is a new advancement in cancer treatment that uses certain components of a ......
Colo-rectal cancer - Management
Treatment for Colorectal Cancers may involve surgery,chemotherapy, radiation therapy or biological t...
Colon Polyps
A colon polyp is a fleshy growth on the inside of the colon, also called the large intestine. In gen...
Colorectal Cancer Screening
Colorectal screening is done using tests to detect blood in stool, colonoscopy or sigmoidoscopy ordo...
Dealing with Pollen Allergy
The plants around you that give you sniffles in your nose at specific time of the year are the sourc...
Tattoos A Body Art
Tattoos are a rage among college students who sport it for the ‘cool dude’ or ‘cool babe’ look...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use